Payment overview · 2025
General Payments
$603.32
39 reported records · 12 companies
Healthcare provider profile · identity verified
Charles D Hernandez, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HATTIESBURG, MS · NPI 1942213103
Verified facts
What the public records show
CMS Open Payments records show Charles D Hernandez, DO received $603.32 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Mounjaro, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $196.60 | 32.6% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.06 | 18.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.45 | 12.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.81 | 7.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.52 | 5.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.78 | 5.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.19 | 3.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.78 | 3.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.23 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.26 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.22 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.42 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $603.32 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $151.36 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.74 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.45 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.45 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.52 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.28 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| VANTA ADAPTIVESTIM Normalized: vanta adaptivestim |
Device | Medtronic, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 125 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
125 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
81 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
117 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1220 | 346 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1025 | 287 |
| Gabapentin | Gabapentin | 688 | 169 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 665 | 85 |
| Losartan Potassium | Losartan Potassium | 532 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 138 |
| Carvedilol | Carvedilol | 407 | 119 |
| Omeprazole | Omeprazole | 380 | 104 |
| Glimepiride | Glimepiride | 361 | 105 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 358 | 98 |
| Tizanidine Hcl | Tizanidine Hcl | 329 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 298 | 74 |
| Furosemide | Furosemide | 297 | 106 |
| Tramadol Hcl | Tramadol Hcl | 288 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 277 | 94 |
| Metformin Hcl | Metformin Hcl | 267 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 73 |
| Allopurinol | Allopurinol | 261 | 69 |
| Potassium Chloride | Potassium Chloride | 245 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 244 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 234 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 59 |
| Trazodone Hcl | Trazodone Hcl | 224 | 61 |
| Pregabalin | Pregabalin | 213 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 60 |
| Donepezil Hcl | Donepezil Hcl | 207 | 56 |
| Metformin Hcl Er | Metformin Hcl | 204 | 57 |
| Alendronate Sodium | Alendronate Sodium | 196 | 50 |
| Meloxicam | Meloxicam | 192 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 189 | 53 |
| Lisinopril | Lisinopril | 179 | 51 |
| Simvastatin | Simvastatin | 179 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 176 | 38 |
| Montelukast Sodium | Montelukast Sodium | 174 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 162 | 25 |
| Spironolactone | Spironolactone | 158 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 157 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 157 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 157 | 46 |
| Buspirone Hcl | Buspirone Hcl | 156 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 45 |
| Dicyclomine Hcl | Dicyclomine Hcl | 144 | 35 |
| Ozempic | Semaglutide | 144 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 19 |
| Jardiance | Empagliflozin | 131 | 29 |
| Linzess | Linaclotide | 125 | 32 |
| Nifedipine Er | Nifedipine | 123 | 32 |
| Chlorthalidone | Chlorthalidone | 121 | 37 |
| Trulicity | Dulaglutide | 117 | 31 |
| Valsartan | Valsartan | 116 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 115 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 109 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 29 |
| Baclofen | Baclofen | 106 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 104 | 18 |
| Promethazine Hcl | Promethazine Hcl | 101 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 27 |
| Naproxen | Naproxen | 98 | 28 |
| Clonidine Hcl | Clonidine Hcl | 96 | 23 |
| Farxiga | Dapagliflozin Propanediol | 95 | 20 |
| Meclizine Hcl | Meclizine Hcl | 94 | 32 |
| Mirtazapine | Mirtazapine | 90 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 24 |
| Atenolol | Atenolol | 89 | 24 |
| Mounjaro | Tirzepatide | 89 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 81 | 64 |
| Famotidine | Famotidine | 80 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 28 |
| Ibuprofen | Ibuprofen | 78 | 26 |
| Levetiracetam | Levetiracetam | 73 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 69 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 13 |
| Sertraline Hcl | Sertraline Hcl | 63 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 20 |
| Topiramate | Topiramate | 55 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 16 |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Eliquis | Apixaban | 52 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 14 |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 15 |
| Prednisone | Prednisone | 50 | 33 |
| Celecoxib | Celecoxib | 49 | 11 |
| Ondansetron Odt | Ondansetron | 49 | 17 |
| Telmisartan | Telmisartan | 49 | 12 |
| Ketoconazole | Ketoconazole | 48 | 18 |
| Lovastatin | Lovastatin | 48 | 12 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Lorazepam | Lorazepam | 46 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 16 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 40 | 14 |
| Fluconazole | Fluconazole | 40 | 20 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Nitroglycerin | Nitroglycerin | 38 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 28 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 13 |
| Cilostazol | Cilostazol | 32 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | 11 |
| Ursodiol | Ursodiol | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Clonidine | Clonidine | 29 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 28 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 26 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 14 |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Nystatin | Nystatin | 23 | 11 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $603.32 · 39 records | ABBVIE INC. | AREXVY, Auvelity, CAPLYTA, CREON, FARXIGA, JARDIANCE, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VANTA ADAPTIVESTIM, VRAYLAR, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error